SUMMARY Background
Proton pump inhibitors (PPI) are among the most widely prescribed drugs to treat gastric acid-related disorders. PPI-induced hypomagnesaemia, a defect in intestinal absorption of Mg 2+ , can be a severe side effect of chronic PPI use.
Aim
To restore serum Mg 2+ concentrations in PPI-induced hypomagnesaemia patients by dietary supplementation with inulin fibres.
Methods
Eleven patients with PPI-induced hypomagnesaemia and 10 controls were treated with inulin (20 g/day). Each trial consisted of two cycles of 14-day inulin treatment followed by a washout period of 14 days. Patients continued to use their PPI. Serum Mg 2+ levels served as the primary endpoint.
Results
Inulin significantly enhanced serum Mg 2+ levels from 0.60 to 0.68 mmol/L in PPI-induced hypomagnesaemia patients, and from 0.84 to 0.93 mmol/L in controls. As a consequence 24 h urinary Mg 2+ excretion was significantly increased in patients with PPI-induced hypomagnesaemia (0.3-2.2 mmol/day). Symptoms related to hypomagnesaemia, including muscle cramps and paraesthesia, were reduced during intervention with inulin.
Conclusion

Inulin increases serum Mg
2+ concentrations under PPI maintenance in patients with PPI-induced hypomagnesaemia.
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BACKGROUND Proton pump inhibitors (PPIs) are used by millions of patients for treatment and prevention of peptic ulcers, gastro-oesophageal reflux disease and NSAID-induced mucosal damage. 1, 2 There is accumulating evidence that PPIs induce hypomagnesaemia. 3, 4 In 2011, the Food and Drug Administration issued a formal warning on PPI-induced hypomagnesaemia. 5 A systematic review from 2012 on 36 cases concluded that PPI-induced hypomagnesaemia represents a class effect as it occurs with all PPIs but is absent with other gastric-suppressing agents such as histamine-2 receptor antagonists. 6 The adverse effect results in a wide spectrum of symptoms including, but not limited to, fatigue, vertigo, lightheadedness, numbness and gastrointestinal complaints. [6] [7] [8] PPI-induced hypomagnesaemia occurs after prolonged PPI use, resolves within days following interruption, but resumption of treatment inevitably results in recurrence. 6, 9 Nevertheless, many patients are dependent on PPIs since they do not respond sufficiently to histamine-2 receptor antagonists. 10 Currently, there is no satisfying treatment strategy that resolves PPI-induced hypomagnesaemia while maintaining the desired acid suppressing effect of PPIs. Oral Mg 2+ supplementation is not sufficient to treat PPI-induced hypomagnesaemia in 25% of PPI-induced hypomagnesaemia patients. 5 This is the reason to search for alternative strategies that allow patients to continue PPI yet protect them against hypomagnesaemia. Mg 2+ loss probably results from intestinal malabsorption of Mg 2+ as renal Mg 2+ retention is unaffected in PPI-induced hypomagnesaemia cases 11, 12 PPIs raise luminal pH which interferes with adequate Mg 2+ uptake in the large intestine. 13 A strategy that centres on acidification of colon might contribute to a more efficient intestinal absorption of Mg 2+ .
Natural bacterial fermentation of carbohydrates and proteins generates short-chain fatty acids, which results in an acidic environment that promotes Mg 2+ solubility and absorption. 14 Inulin is a naturally occurring oligosaccharide that upon fermentation by colonic bacteria results in a decrease of pH. [15] [16] [17] [18] [19] In experiments with rodents, inulin actually increased the intestinal uptake Ca 2+ . 20 Therefore, inulin may serve to increase serum Mg 2+ concentrations in patients with PPI-induced hypomagnesaemia.
In a series of n-of-1 crossover trials, we treated patients with PPI-induced hypomagnesaemia with inulin supplementation with the aim to evaluate changes in serum Mg 2+ concentrations under continuous PPI use.
By this approach we aimed to obtain scientifically robust ('level 1') evidence of benefits and harms of inulin treatment for PPI-induced hypomagnesaemia.
METHODS
Series of n-of-1 trials
The trial protocol was approved by the local ethics committee (METC Arnhem Nijmegen, the Netherlands) and the study was performed according to the declaration of Helsinki. All patients provided written informed consent. The trial was registered at clinicaltrials.gov (NCT02518659). All study investigators had access to the study data, reviewed and approved the final manuscript. Cases with PPI-induced hypomagnesaemia were collected between 2012 and 2014 in the Radboud University Medical Center (Nijmegen, the Netherlands), Canisius Wilhelmina Ziekenhuis (Nijmegen, the Netherlands) and Bernhoven Ziekenhuis (Oss, the Netherlands). To be included patients should be chronic users of PPIs and suffer from PPI-induced hypomagnesaemia. Patients with uncontrolled diabetes were excluded from enrolment. Healthy controls were recruited from the community using advertisements in the local media. Patients with PPI-induced hypomagnesaemia and healthy controls participated in an intervention trial which used orally administered fructooligosaccharide inulin fibres. Participants were provided with portions of 20 g inulin (Synergy 1; Orafti-Beneo, Tienen, Belgium) to be consumed with meals. Patients were asked to maintain their dietary habits and to continue the use of PPIs.
Aim and objectives
We aimed to improve and to individualise treatment of patients with hypomagnesaemia using a series of n-of-1 trials to decipher benefits and harms of inulin treatment for PPI induced hypomagnesaemia. This study was designed as a single-centre, controlled, multiple crossover n-of-1 studies. Total study duration was 56 days, divided into 4 periods of 14 days each (Figure 1 ). During days 0-14 and days 28-42 all participants were given inulin in a dosage of 20 g/day, which is in the same range as other studies. 19 Each of the treatment phases was followed by a washout phase of 14 days. To deal with the correlation of the repeated measured outcome within a single patient, a random intercept was included in the model. The model assumes that the effect of treatment can be different for the two patient groups (interaction) and that correlations between two measurements within a patient is the same for each combination. Using the mixed model, the treatment effect, that is, the difference of the mean outcome using inulin minus the mean outcome without inulin, for both patient groups was estimated and tested. Averaged values were reported as mean AE S.E.M.
Measurements
RESULTS
Demographics
Twenty-six patients (11 PPI-hypomagnesaemia patients and 15 healthy non-PPI using controls) were contacted for participation ( Figure 1 ). All patients (6 male, 5 females, mean age 64 years-of-age, range 46-76 years-ofage) consented. We excluded five controls, due to intestinal complaints (n = 1), unwillingness to adhere to the study protocol (n = 1), intercurrent illness (n = 1) or loss of interest (n = 2). This resulted in a final study population of 11 cases and 10 healthy controls (Table 1) .
Patients with PPI-induced hypomagnesaemia used omeprazole (n = 6), pantoprazole (n = 3) or esomeprazole (n = 2) and the doses ranged from 20 to 60 mg/day. In all included patients, PPIs were temporarily stopped at one stage in their disease to show that hypomagnesemia is caused by PPI use. However, all of them reinitiated PPI treatment for gastrointestinal protection. During the study all patients continued their PPI treatment.
Inulin increases serum Mg 2+ concentrations
Proton pump inhibitor-induced hypomagnesaemia patients had mean baseline serum Mg 2+ concentration of 0.60 AE 0.03 mmol/L, which increased to 0.68 AE 0.03 mmol/L (P < 0.01) after the first course of 2 weeks of inulin supplementation (Figure 2a) . Similarly, the second inulin course also enhanced serum Mg 2+ concentrations from 0.61 AE 0.03 to 0.69 AE 0.03 mmol/L (P < 0.01).
In controls, serum Mg 2+ levels increased significantly during the second course of 2 weeks (0.84 AE 0.02 to 0.93 AE 0.03 mmol/L, Figure 2c ). To determine a global treatment effect, we performed a mixed models analysis was performed that demonstrated that inulin 
Inulin and electrolyte homeostasis
To determine the specificity of the effect of inulin supplementation on electrolyte homoeostasis, serum Ca 2+ , Na + and K + levels were determined. During the first inulin course, serum Ca 2+ concentrations increased in patients (2.27 AE 0.04 to 2.41 AE 0.04 mmol/L; P < 0.01, Figure S1a) . Similarly, the control group showed a significant increase in serum Ca 2+ concentrations only in the second treatment period (P < 0.05, Figure S1c ). Mixed models analysis with data from both 2-week treatment courses demonstrated an increase in serum Ca Figure S2a ). The overall mean treatment effects for inulin on serum K + were significant for patients with a net increase in 0.26 mmol/L (P < 0.01), as determined by mixed models analysis ( Figure S2a,b) . Finally, inulin did not affect serum Na + concentrations in both patients and control ( Figure S2c,d ).
Symptoms
Seven patients with PPI-induced hypomagnesaemia reported symptoms likely attributed to hypomagnesaemia (Table 2 ). Most frequently reported were paraesthesia in hands and feet, muscle cramps, generalised weakness, in side effects such as diarrhoea and are insufficient to raise Mg 2+ levels in PPI users. 22 Inulin is able to increase serum Mg 2+ in PPI-induced hypomagnesaemia patients and in healthy controls, but the magnitude of increase in patients exceeded that of controls by a factor two. These results are in line with previous observations documenting that inulin fibres enhance Mg 2+ absorption in human volunteers. 19, 23 The dose of 20 g/day is based on previously published studies that used inulin to increase intestinal absorption of Ca 2+ or Mg 2+ . The commonly used dose in this type of experiments ranges between 10 and 40 g/day. 19 Our dose of 20 g/day is in the centre of this spectrum. The beneficial effects of inulin supplementation were not restricted to Mg 2+ but extended to other electrolytes such as Ca 2+ and K + . Although serum Ca 2+ and K + levels were in the normal range in our study population, there have been reports of hypocalcaemia and hypokalaemia associated with PPI use. 6 We observed an increase in serum Ca 2+ and K + levels that stayed within the normal range.
In line with earlier studies in healthy patients using PPI, our PPI-induced hypomagnesaemia patients had marginally decreased 24-h urinary Ca 2+ excretion. 24 Low-serum Mg 2+ suppresses parathyroid hormone secretion which reduces Ca 2+ absorption and puts patients at risk for bone-fractures and/or osteoporosis. 25 Inulin raised renal Ca 2+ excretion in our population, resulting from stimulated intestinal Ca 2+ absorption which is reflected in a net increase Ca 2+ serum level. As such, this effect may contribute to the protection against osteoporosis in chronic PPI users. 26 The fact that inulin increases serum Mg 2+ , Ca 2+ and K + in this trial suggests a general mechanism of action.
A plausible hypothesis proposes that colonic fermentation of inulin drives short-chain fatty acid production that lowers intestinal pH and ultimately improves the solubility of minerals. 31 These findings may explain why the effects of inulin on Mg 2+ absorption are stronger than on the uptake of other ions. The use of inulin comes with gastrointestinal complaints such as flatulence and boborygmi. However, these side effects were mainly reported within the first 2-3 days after the start of the inulin treatment. These events reflect a transient adaptation to inulin treatment and disappeared with prolonged treatment. Therefore, we consider the 20 g/day dose as well-tolerated in PPI patients. This is supported by the fact that all the PPIinduced hypomagnesaemia patients completed the full 56-day trial period.
Our study comes with strength and limitations. The introduction-withdrawal design included two cycles of inulin-based treatment. Such a design delivers evidencebased results and is easily translatable to a large variety of settings within daily clinical practice. 32 The clinical effect on Mg 2+ serum levels during both cycles was highly reproducible in and between patients suggesting a true treatment effect. The washout time was determined on basis of a previous systematic review that indicated that the PPI-induced hypomagnesaemia is reversible in a few (<5) days. 6 As such we avoided a carry-over effect that was documented by the finding that serum Mg 2+ Patients (n = 11) Controls (n = 10) Patients (n = 11) Controls (n = 10)
Values represent number of patients.
returned to baseline levels within 14 days in all patients. PPI-induced hypomagnesaemia is a rarely reported side effect of PPI use and a recent review identified 36 globally published cases of PPI-induced hypomagnesaemia. 6 It is, therefore, difficult to conduct group-RCTs to determine its effectiveness. N-of-1 trials may provide a way of gathering scientifically robust evidence of effectiveness in small patient groups. N-of-1 trials are randomised, controlled, multiple crossover trials in single patients, in which data are contributed over several treatment cycles.
Evidence from several n-of-1 trials can be aggregated to produce population treatment effect estimates. We used a multiple crossover n-of-1 trial so that each patient acted as own control and contributed multiple cycles of data. A limitation of this design is the absence of blinding. We were able to trial 11 patients who were able to cycle through all treatment periods. Effects were consistent between treatment periods which suggests that the robustness of the design.
In conclusion, we demonstrated that inulin stimulates intestinal mineral uptake. Although not all patients reached normal serum Mg 2+ levels after inulin treatment, 
